Show All

Our philosophy on investor relations is to present accurate, transparent information to the investing community, which enables each investor to make appropriate decisions for themself. Our mandate is not to attempt to manage the short-term share price; it is to advance our rare disease pipeline and build and grow the company to reach its full potential over the long term. Drug development is not a short-term endeavor and progress is not always reflected in the stock price in the short term. We believe if we remain focused and execute on our longterm objectives, this will deliver value to patients and shareholders in the future.

Our efforts to optimize Saniona’s investor communication are ongoing. Some improvements that we have already made to provide greater transparency, information and service for our investors include: switching the provider of ownership data on the website, implementing a system to triage and respond to investor inquiries, conducting an investor monitor/survey to understand investor perceptions, adding detail to the analyst coverage page on the website, creating this FAQ document, and enhancing our interaction with analysts and media to provide greater visibility for Saniona. During the first half of 2021 we launched a new website with updated design and layout and in May 2021 we held a digital R&D Day. We look forward to continuing these and other improvements - such as further enhancing our analyst and media communications, and additional initiatives - all in order to better highlight and communicate Saniona’s business strategy and investment case. We are committed to controlling the things we can control and ultimately bringing medicines to patients who need them.

Our strategy is to discover, develop and commercialize innovative treatments for patients suffering from rare diseases around the world. We intend to achieve this by advancing our ion channel modulators, SAN711 and SAN903, for rare neuropathic and rare inflammatory, fibrotic and hematological disorders, respectively, and by pursuing strategic financing options and business development opportunities that could allow Tesomet to advance in HO and PWS.

Saniona’s corporate strategy is to develop new medicines for rare disease. There is a tremendous unmet need within the rare disease patient population: there are an estimated 7,000 rare diseases, and less than 10% have FDA-approved treatments. Additionally, many rare diseases lead to the premature deaths of infants and young children. The potential to bring medicines to these patients can have a significant impact. Additionally, clinical trials and regulatory reviews of medicines for rare diseases can potentially require less time and/or less financial investment than in more common, larger disorders, therefore making rare diseases better aligned with Saniona’s capabilities as a small biotech company.

Saniona’s shares are listed at Nasdaq Stockholm, small cap, under the ticker SANION.

Saniona focuses on developing medicines for rare diseases. Developing drugs requires large investments of capital. Saniona thus does not plan to pay any dividends for the foreseeable future. 9. Who are the largest shareholders in Saniona? Consistent with all Swedish listed companies, we disclose Saniona’s ownership structure (top 10 owners) on our website. Market practice for Swedish companies is that the information is updated quarterly, but we have recently chosen to update the list monthly to maintain a higher level of transparency. You can find more about Saniona’s ownership structure in the Investors section of our web site, on the page titles “Ownership Structure.”

You can find more information about Saniona’s current analyst coverage on the Investor section of the website, on the page titled “Analyst Coverage.”

You can download a pdf of Saniona’s interim and annual reports from the Investors Section of Saniona’s web site, on the page titled “Financial Reports.”

Saniona’s clinical trials have not been significantly impacted by the ongoing COVID-19 pandemic. We have licensed some of our technologies to third parties, and their development efforts have been and may continue to be impacted by the ongoing COVID-19 pandemic. There are still uncertainties with regard to the continued spread of COVID-19, including the identification of new variants of the virus and its implications, and we will continue to assess the situation and seek to put in place relevant mitigating measures where necessary.

Although we believe we have implemented strategies to potentially minimize the impact of the COVID-19 pandemic to our business, including following local recommendations regarding COVID-19 safety, we may experience delays with respect to the initiation of certain additional trials or receipt of any governmental or regulatory approvals. The extent to which the COVID-19 pandemic impacts the timing of these matters will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the identification of new variants of the virus, the duration of the pandemic, any restrictions on the ability of hospitals and trial sites to conduct trials that are not designed to address the COVID-19 pandemic and the perceived effectiveness of actions taken in the United States and other countries to contain and treat the disease. We will continue to evaluate the impact of the COVID-19 pandemic to our business.

Do you have a question that was not addressed in this FAQ? Contact us at